Calyx Reports Change of Auditor
May 25 2014 - 11:50PM
Marketwired
Calyx Reports Change of Auditor
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 25, 2014) -
Pursuant to section 4.11 of National Instrument 51-102, Calyx
Bio-Ventures Inc. (TSX-VENTURE:CYX) ("Calyx" or the "Company")
announces it has changed auditors and has filed a reporting package
at www.sedar.com with respect to the change of auditor.
The reporting package contains the following documents:
- an executed Notice of Change of Auditor;
- a letter to the former auditor, Ernst & Young, LLP
("E&Y);
- a letter from the successor auditor Dale Matheson Carr-Hilton
Labonte LLP;
- a letter from the former auditor, E&Y; and
- a letter confirming that the above-listed documents have been
reviewed by the Board of Directors of the Company.
About Calyx
Calyx Bio-Ventures Inc. (TSX-VENTURE:CYX) is an agricultural
technology company which is developing early stage agriculture
ventures. Calyx brings its depth of experience, capital and other
capacity including its proprietary intellectual property to enhance
plant yields. In addition to Calyx's position as a shareholder of
Agrisoma Biosciences Inc., a company which is producing a non-food
energy feedstock crop for bioenergy, Calyx is pursuing
agri-pharmaceutical opportunities in the MMPR (Marijuana for
Medical Purposes Regulations) and the agri-tech space. For further
information about Calyx, please visit www.calyxbio.com.
Forward-Looking Statements: This document contains certain
forward-looking statements concerning Calyx, as well as other
expectations, plans, goals, objectives, information or statements
about future events, conditions, or performance that may constitute
"forward-looking statements" or "forward-looking information" under
applicable securities legislation. Such statements or information
involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control.
Such forward-looking statements or information are based on
a number of assumptions, which may prove to be incorrect.
Although Calyx believes that the expectations reflected in
such forward-looking statements or information are reasonable,
undue reliance should not be placed on forward-looking statements
because Calyx can give no assurance that such expectations will
prove to be correct. Forward-looking statements or information are
based on current expectations, estimates and projections that
involve a number of risks and uncertainties which could cause
actual results to differ materially from those anticipated by Calyx
and described in the forward-looking statements or
information.
The forward-looking statements or information contained in
this news release are made as of the date hereof and Calyx
undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by
applicable securities laws or the TSX Venture Exchange. The
forward-looking statements or information contained in this news
release are expressly qualified by this cautionary
statement.
Neither the
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
Calyx Bio-Ventures Inc.Don KonantzPresident &
CEO604-649-5961dkonantz@calyxbio.comCalyx Bio-Ventures Inc.Investor
Relations:Keir
Reynolds778-998-9242kreynolds@calyxbio.comwww.calyxbio.com
Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From Apr 2024 to May 2024
Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From May 2023 to May 2024